18 March 2021
ResistancePlus® tests validated for cobas z 480 Analyzer
Roche customers will now have even more opportunities to utilise ResistancePlus® tests to support clinically important treatment decisions. SpeeDx ResistancePlus®...
3 February 2021
Continued Syphilis Outbreak Warrants National Attention
Syphilis remains an important public health concern due to global case increases. In Australia, the largest syphilis outbreak ever recorded...
10 November 2020
SpeeDx Partners with Nepean Hospital to Develop Risk-Based COVID-19 Management Test
SpeeDx have partnered with researchers from Nepean Hospital in an exclusive agreement to commercialise a molecular test for IFI27 -...
27 October 2020
SpeeDx opens PC2 laboratory facility
The opening of a PC2 laboratory facility at SpeeDx Sydney headquarters is an exciting milestone to celebrate. SpeeDx performs all...
3 September 2020
SpeeDx and Nepean Hospital Awarded Federal Funding for Viral Respiratory Biomarker Test
SpeeDx in partnership with Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital Intensive Care Unit were awarded funding through...
11 August 2020
Clinical data supports Resistance Guided Therapy for gonorrhoea
Important clinical data published in Clinical Infectious Diseases demonstrated practical effectiveness of Resistance Guided Therapy for treating gonorrhoea. Led by...
